Shorts

Arturo Loaiza-Bonilla, MD, MSEd, FACP, discussed the ability of large foundational AI models to democratize pathology readouts by providing biomarkers with an H&E stain or a slide in the absence of readily available pathologist.

1:29

Democratizing Pathology in Oncology with Artificial Intelligence

17 days ago

Arturo Loaiza-Bonilla, MD, MSEd, FACP

1:12

Neoadjuvant Radiation in Sarcoma: Does it Change Surgical Ease?

17 days ago

Emily J. Papai, MD

0:41

Why Early Dietary Support in Cancer is Vital

17 days ago

Ifeoma Dikeocha, PhD

In this video, Arturo Loaiza-Bonilla, MD, MSEd, FACP, discussed best use cases for artificial intelligence (AI) in oncology.

0:52

Outlining Best Use Cases For AI in Oncology

22 days ago

Arturo Loaiza-Bonilla, MD, MSEd, FACP

0:52

AI May Function Like “Connective Tissue” in the Clinical Oncology Continuum

24 days ago

Arturo Loaiza-Bonilla, MD, MSEd, FACP

Brandon Mancini, MD, MBA, FACRO, introduces the RadOnc on the Run podcast, a program dedicated to discussing critical advances and considerations in radiation oncology care and research.

1:03

Introducing RadOnc on the Run: CancerNetwork’s New Podcast Initiative

a month ago

Brandon Mancini, MD, MBA, FACRO

Soumen Das, MS, FACS, MRCS, FRCS, outlined 3 pillars for breast cancer the GBCI, a wing of the WHO outlined among other key performance indices (KPIs) for breast cancer care.

0:49

Aligning With the WHO GBCI: 3 Pillars for Breast Cancer Treatment

a month ago

Soumen Das, MBBS, MS, FACS

Soumen Das, MS, FACS, MRCS, FRCS, discussed the integration of a breast cancer reporting and data system (BCRADS) for low- and middle-income countries to help improve outcomes in low resource settings (LRS).

0:46

Decentralizing Breast Oncology Care in LMIDs Through Clinical Reporting/Data System

a month ago

Soumen Das, MBBS, MS, FACS

Surbhi Sidana, MD, associate professor of medicine and lead of the Myeloma CAR-T/Immunotherapy Program at Stanford University in California, discussed the importance of funding for hematologic oncology research in an interview with CancerNetwork®.

0:40

NIH Funding May Be Instrumental to Developing Multiple Myeloma Research

a month ago

Surbhi Sidana, MD

$Surbhi Sidana, MD, discussed what implications the approval of teclistamab plus daratumumab among patients with relapsed/refractory multiple myeloma would have on practice for this disease.$

1:04

Daratumumab/Teclistamab Multiple Myeloma Approval Could Expand Treatment Options

a month ago

Surbhi Sidana, MD

Nathan Goodyear, MD, touched upon research which might suggest that malignant cancer cells may be able to be transformed back to normal functioning ones.

1:24

Could Malignant Cancer Cells Be Transformed Back to Normal Functioning Ones?

a month ago

Nathan Goodyear, MD

1:16

Restoring the Patient-Doctor Relationship Through Collaboration in Integrative Oncology

a month ago

Nathan Goodyear, MD

Ash Tewari, MBBS, MCh, FRCS, discussed the impact that a mobile prostate cancer testing unit has had on the local community.

0:52

Unplanned Mobile Unit Testing Identified Early-Stage Prostate Cancer

a month ago

Ash Tewari, MD, MBBS, MCh, FRCS

In this video, Tewari highlighted developments in nerve-sparing prostate cancer procedures, with a particular emphasis on one that is aimed at preserving erectile function following surgery.

0:41

Recovering Sexual Function Through Nerve-Sparing GU Procedures

a month ago

Ash Tewari, MD, MBBS, MCh, FRCS

For this video, Janjigian highlighted the unifying impact of the MATTERHORN trial, which established perioperative immunotherapy among this patient group regardless of location.

1:27

Unifying Perioperative Immunotherapy Globally in Gastric Cancer Treatment

a month ago

Yelena Y. Janjigian, MD

Janjigian discussed the role of pathologic complete response rate as an early indicator for cure among patients with gastric cancer, particularly in the absence of long-term survival data.

0:56

Pathologic CR Rates May Provide Early Indicator of Cure in Gastric Cancers

a month ago

Yelena Y. Janjigian, MD

Janjigian touched upon key design elements of the MATTERHORN trial, which sought to assess the safety and efficacy of the FLOT-based combination among patients with gastric cancer globally.

0:56

Treating Gastric Cancer With “Modern” FLOT Backbone Regardless of PD-L1 Status

a month ago

Yelena Y. Janjigian, MD

In an interview with CancerNetwork®, Nathan Goodyear, MD, discussed the creation of "hot" tumor microenvironment through integrative oncology strategies.

1:19

Creating an Immune “Hot” Tumor Microenvironment Through Integrative Oncology

2 months ago

Nathan Goodyear, MD

James R. Berenson, MD, outlined the benefits of the text-based monitoring of symptoms and quality of life (mQOL) platform on patient-reported outcomes (PROs) in clinical practice at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition.

0:51

Spotlighting a 3-Minute mQOL Questionnaire for PROs in Hematology

2 months ago

James R. Berenson, MD, FACP

$Krina K. Patel, MD, MSc, discussed the efficiency of the mechanism of action for anito-cel, which uses a smaller protein to increase the frequency of CAR transductions in patients undergoing treatment for relapsed/refractory multiple myeloma.$

0:46

Maximizing CAR T-cell Efficiency in Multiple Myeloma Through the D-Domain

2 months ago

Krina K. Patel, MD, MSc